Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS IDES AFTER ADMINISTRATION OF ASCENDING DOSES IN CHRONIC KIDNEY DISEASE PATIENTS

Trial Profile

A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS IDES AFTER ADMINISTRATION OF ASCENDING DOSES IN CHRONIC KIDNEY DISEASE PATIENTS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlifidase (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Hansa Biopharma AB; Hansa Medical AB
  • Most Recent Events

    • 03 Jun 2020 Results assessing whether imlifidase has an effect on human anti-HLA IgM antibodies in sensitized patients with end stage renal disease, presented at the 2020 American Transplant Congress
    • 18 Sep 2019 According to a Hansa Biopharma AB media release, pooled data from this and other three studies (244081, 269806 and 305829) were presented at the 19th Congress of the European Society for Organ Transplantation (ESOT) 2019 in Copenhagen, Denmark.
    • 12 Mar 2018 Results (n=8) assessing safety and efficacy of IdeS in chronic kidney disease, were published in the American Journal of Transplantation.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top